Gilead HCV Heart and Lung - A Multicenter, open-label study of Harvoni® (sofosbuvir-ledipasvir fixed dose combination) in subjects infected with chronic hepatitis C and advanced heart failure or lung disease
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
Gilead Sciences, Inc.
Start Date
September 1, 2016
End Date
August 31, 2020
Administered By
Medicine, Gastroenterology
Awarded By
Gilead Sciences, Inc.
Start Date
September 1, 2016
End Date
August 31, 2020